Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC)

Abstract

4713 Background: Two recent phase III trials have shown an improvement in survival with the use of Docetaxel in metastatic androgen-independent prostate cancer (AIPC) compared to mitoxantrone. However no phase II trials have clearly defined the level of activity of docetaxel after mitoxantrone. We sought to define the activity and toxicity of weekly docetaxel as second line chemotherapy after mitoxantrone in men with AIPC. Patients and Methods: 20 men were treated with docetaxel 40mg/m2 weekly for 3 of every 4 weeks until progression or prohibitive toxicity. Endpoints included PSA response, CTC toxicity, time to progression and overall survival. Results: 9 patients (45%) had a 50% or greater reduction in PSA maintained for at least 1 month. Weekly Docetaxel was well tolerated with few major toxicities: 2 patients had Grade 3 diarrhoea (10%), and 6 had grade 2–4 haematologic toxicities (30%). The median time to progression was 5 months (range 0–13) and median survival was 13 months (range 1 to 24) from starting Docetaxel.The median survival from starting mitoxantrone was 19 months Men who had responded to mitoxantrone were no more likely to respond to Docetaxel (p=0.16 Fischer’s exact test) Conclusions: Weekly Docetaxel is a safe and active second line treatment after mitoxantrone for androgen-resistant prostate cancer with similar levels of activity to the first line setting. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis Eli Lilly Aventis, Eli Lilly